Apple co founder Steve Jobsis looking to expand investments in British healthcare startups through its oncology-focused venture firm as it pushes efforts to improve cancer treatment and early detection.Jobs, 34, runs Yosemite, a San Francisco-based venture firm that manages more than $1 billion in assets and backs companies developing cancer therapies, gene-editing technologies, radiopharmaceuticals and artificial intelligence tools for health care.Speaking during the Translational Research Summit organized by LifeArk in London, Jobs explained how his father’s battle with cancer focused his attention on oncology research and investment, reports The Guardian.“When I was a kid, I watched my father have cancer, and unfortunately that happens very often,” Jobs said at the summit.“And that really inspired me to try to change outcomes for other people.”Steve Jobs died in 2011 at the age of 56 after battling a rare form of pancreatic cancer.Jobs said that Yosemite is actively exploring opportunities in the UK and meeting with pharmaceutical companies, academics and researchers as part of its international investment plans.“As a firm, we invest in companies internationally, and we would love to see opportunities in the UK,” he said.Yosemite has invested in about 20 healthcare startups, including companies working on cancer vaccines, gene therapy and AI-powered drug development. The firm has also backed some UK-based companies that have not yet been publicly announced.The venture was launched in 2023 after it spun off from Emerson Collective, the investment and philanthropic organization founded by Jobs’ mother Laurene Powell Jobs.Yosemite is supported by several leading institutions and investors, including Amgen, the Massachusetts Institute of Technology, and Memorial Sloan Kettering Cancer Center.Jobs said he hoped that future advances in medicine would turn cancer into a disease that could be detected earlier and treated more effectively.“Many cancers these days are either diagnosed incidentally, because there are no good early biomarkers, or diagnosed only after they are metastatic and extremely advanced,” he said.“this is unacceptable.”He described immunotherapy as one of the most promising areas in cancer treatment in the coming decades.“I think this is one of the areas that will have the most potential for patients over the next few decades,” Jobs said.